Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024
During the experimentation, 3% of patients treated with MC experienced at least one serious ADR. The safety profile was dominated by neurological, gastrointestinal, and psychiatric ADRs. Only one case of MC misuse was identified with inflorescences. This study is observational and non-comparative and cannot provide a comprehensive assessment of the risk associated with MC use.
Authors
- Basile Chrétien (ORCID: https://orcid.org/0000-0002-7483-2489)
- Sophie Fédrizzi
- Véronique Ferey
- Louise Gaboriau (ORCID: https://orcid.org/0000-0002-1367-5109)
- Emilie Monzon
- Nicolas Authier
- Marine Auffret
- Cécile Chevallier
- Anne Batisse
- Chouki Chenaf
- Nathalie Richard
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospices Civils de Lyon (FR)
- Groupe de Recherche sur l'Alcool et les Pharmacodépendances (FR)
- Agence Nationale de Sécurité du Médicament et des Produits de Santé (FR)
- Observatoire de Physique du Globe de Clermont-Ferrand (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Laboratoire de Biométrie et Biologie Evolutive (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- Fundamental and Clinical Pharmacology
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1111/fcp.70074
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00